ImaRx Therapeutics, which is developing novel therapies for vascular disorders associated with blood clots, lowered its expected price Friday to $5 per share from its originally proposed range of $6.50 to $7.50 per share. Maxim group is the lead manager on the deal.
IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
